Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...
Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first ...
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today ...
On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug ...
Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially ...
Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.
CASTRES, France & BOSTON--(BUSINESS WIRE)--Pierre Fabre Laboratories, a global player in oncology, and Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results